Investigational Drug Information for Odanacatib
What is the development status for investigational drug Odanacatib?
Odanacatib is an investigational drug.
There have been 19 clinical trials for Odanacatib.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2008.
The most common disease conditions in clinical trials are Osteoporosis, Osteoporosis, Postmenopausal, and Breast Neoplasms. The leading clinical trial sponsors are Merck Sharp & Dohme Corp. and [disabled in preview].
Summary for Odanacatib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 501 |
| WIPO Patent Applications | 136 |
| Japanese Patent Applications | 22 |
| Clinical Trial Progress | Phase 3 (2008-09-01) |
| Vendors | 57 |
Recent Clinical Trials for Odanacatib
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076) | Merck Sharp & Dohme Corp. | Phase 3 |
| A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066) | Merck Sharp & Dohme Corp. | Phase 1 |
| Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050) | Merck Sharp & Dohme Corp. | Phase 3 |
Clinical Trial Summary for Odanacatib
Top disease conditions for Odanacatib
Top clinical trial sponsors for Odanacatib
US Patents for Odanacatib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Odanacatib Development Update, Patent Status, and Market Projection
Odanacatib, Merck’s investigational cathepsin K inhibitor, is no longer an active clinical-development program. Merck discontinued development in 2016 after the Phase 3 LOFT study identified an increased risk of stroke. The drug never received FDA approval, has no Orange Book listing, and has generated no commercial product revenue. Its near-term market projection is therefore zero unless a sponsor restarts development with a materially different benefit-risk strategy.
What is the current development status of odanacatib?
Odanacatib, also known as MK-0822, was developed as an oral, once-weekly treatment for postmenopausal osteoporosis. It selectively inhibited cathepsin K, an enzyme involved in osteoclast-mediated bone resorption.
Merck evaluated odanacatib in a large global Phase 3 program known as LOFT, or Long-Term Odanacatib Fracture Trial. The study enrolled more than 16,000 postmenopausal women with osteoporosis and assessed fracture outcomes over several years.
The key development milestones were:
| Milestone | Date | Status |
|---|---|---|
| Discovery and early clinical development | Before 2010 | Completed |
| Phase 3 LOFT osteoporosis study | 2009-2012 enrollment period | Completed |
| Positive fracture and bone-density findings | 2015 | Reported |
| Merck discontinued development | September 2016 | Program terminated |
| FDA approval | None | Not filed or not approved |
| Commercial launch | None | No product sales |
Merck reported that odanacatib reduced vertebral, hip and nonvertebral fracture risk in the LOFT study. The company stopped further development after an independent review identified a higher risk of stroke in patients receiving odanacatib compared with placebo (Merck, 2016).
Why did Merck discontinue odanacatib?
The principal reason was an unfavorable overall benefit-risk profile caused by cerebrovascular safety findings.
Merck reported that the study met its efficacy objectives, including reductions in vertebral and hip fractures. The same study showed an increased risk of stroke. The safety signal affected the regulatory viability of the product because osteoporosis treatment is preventive, long-term and often prescribed to patients who may have multiple cardiovascular risk factors.
Odanacatib’s mechanism created a potential differentiation from existing antiresorptive therapies. Cathepsin K inhibition could suppress bone resorption while preserving some osteoclast activity and potentially supporting bone formation. The clinical data did not overcome the stroke concern.
The discontinuation removed the leading clinical program in the cathepsin K inhibitor class. No subsequent sponsor has publicly advanced odanacatib into a new Phase 3 program.
What FDA regulatory status does odanacatib have?
Odanacatib has no FDA approval and no publicly established commercial regulatory pathway.
| Regulatory category | Odanacatib status |
|---|---|
| FDA approval | None |
| New Drug Application approval | None |
| Approved indication | None |
| FDA exclusivity | None |
| Orange Book listing | None |
| Authorized dosage form | None |
| Pediatric exclusivity | None |
| Biosimilar pathway | Not applicable |
Because odanacatib is a small molecule rather than a biologic, a future sponsor would likely pursue a conventional 505(b)(1) New Drug Application if it generated a new clinical package. A 505(b)(2) pathway could be considered only if the sponsor relied on previously established findings in a legally and scientifically acceptable manner. The discontinued Phase 3 data would not eliminate the need to resolve the stroke risk.
What patents protect odanacatib?
Odanacatib was protected by a historical patent estate covering the active compound, related chemical structures, pharmaceutical compositions, and methods for treating bone disorders. Merck was the principal development company and patent holder associated with the program.
The commercial value of that estate has declined sharply because:
- Development was terminated before approval.
- No FDA-approved product exists.
- Patent expiry periods continue to run regardless of the abandoned program.
- The clinical safety issue reduces the value of a patent-based generic-exclusion strategy.
- There is no Orange Book-listed patent available to support a Paragraph IV litigation campaign.
The relevant patent categories included:
| Patent category | Commercial purpose |
|---|---|
| Compound patents | Protect odanacatib and related chemical entities |
| Pharmaceutical composition patents | Cover drug formulations and dosage forms |
| Method-of-use patents | Cover treatment or prevention of osteoporosis and fractures |
| Process patents | Cover manufacturing routes or intermediates |
| Crystalline-form or salt patents | Potentially protect physical forms and solid-state properties |
Exact live patent rights depend on jurisdiction, patent family, terminal disclaimers, maintenance payments and national expiration calculations. The discontinued clinical program does not create an approved-product patent term extension. In the United States, no Orange Book-listed odanacatib patent exists because no NDA was approved.
When does odanacatib lose exclusivity?
Odanacatib has no regulatory exclusivity period because it was never approved.
The practical exclusivity position is different from that of an approved medicine:
| Exclusivity type | Status |
|---|---|
| New chemical entity exclusivity | Never granted |
| Orphan-drug exclusivity | Not established |
| Pediatric exclusivity | Not granted |
| Patent term extension | No approved product basis |
| Orange Book patent protection | None |
| Marketed-product exclusivity | None |
Historical compound and process patents may still have had residual life after Merck ended development, but those rights do not create a viable commercial monopoly without an approved product. A future sponsor would need to assess remaining patent terms and regulatory data rights separately.
Was odanacatib subject to Paragraph IV challenges?
No commercially significant Paragraph IV challenge is associated with odanacatib.
Paragraph IV litigation normally arises when a generic applicant files an Abbreviated New Drug Application challenging Orange Book-listed patents for an approved reference drug. Odanacatib never became an approved reference product, so the normal ANDA and Paragraph IV framework did not develop.
There is no established generic launch date, first-filer exclusivity period or Hatch-Waxman settlement involving odanacatib.
What formulations were protected by odanacatib patents?
The clinical program evaluated oral, once-weekly dosing. Public development materials describe odanacatib as an oral tablet candidate. The formulation strategy was commercially attractive because osteoporosis patients often face adherence problems with daily or weekly dosing regimens.
Historical patent protection likely addressed pharmaceutical compositions containing odanacatib with conventional excipients and oral dosage forms. Composition claims can be commercially useful only if they survive validity and infringement challenges and if the underlying drug reaches the market.
No approved extended-release, injectable, transdermal or implantable odanacatib formulation exists. No authorized combination product exists.
What was the clinical evidence for odanacatib?
The LOFT study produced clinically meaningful efficacy results. Merck reported that, after several years of treatment, odanacatib reduced:
- New vertebral fractures.
- Hip fractures.
- Nonvertebral fractures.
- Bone mineral density loss.
The principal commercial appeal was the combination of strong anti-fracture efficacy, oral dosing and a mechanism distinct from bisphosphonates and RANK ligand inhibition.
The safety profile prevented regulatory progression. Stroke risk was the decisive issue, not a lack of pharmacologic activity.
How does odanacatib compare with competing osteoporosis drugs?
Odanacatib would have entered a market dominated by established antiresorptive therapies and newer anabolic or bone-forming agents.
| Drug or class | Mechanism | Administration | Commercial position relative to odanacatib |
|---|---|---|---|
| Alendronate and other bisphosphonates | Inhibit osteoclast-mediated bone resorption | Usually oral or intravenous | Low-cost, established first-line therapy |
| Denosumab | RANK ligand inhibitor | Subcutaneous injection every six months | Strong efficacy and broad use |
| Zoledronic acid | Bisphosphonate | Intravenous, typically annual | Useful for adherence-sensitive patients |
| Teriparatide and abaloparatide | Anabolic bone formation | Daily injection | Used for high fracture risk |
| Romosozumab | Sclerostin inhibitor | Monthly injection | Anabolic and antiresorptive activity; cardiovascular restrictions |
| Odanacatib | Cathepsin K inhibitor | Oral, once weekly in development | Discontinued because of stroke risk |
Odanacatib’s strongest potential differentiation was a weekly oral regimen with robust fracture efficacy. Its largest disadvantages were the stroke signal and the availability of lower-cost generic bisphosphonates.
What is the market projection for odanacatib?
The base-case market projection is zero through the near term because odanacatib is not approved, not marketed and not in active clinical development.
A restart would require more than a licensing transaction or a new formulation. The sponsor would need to establish that the stroke risk can be reduced, explained or managed. That would likely require new clinical work and a revised regulatory strategy.
| Scenario | Probability assessment | Commercial outcome |
|---|---|---|
| No redevelopment | Base case | No revenue |
| Academic or private-sector re-evaluation | Low | Early-stage asset value only |
| Merck or another sponsor restarts clinical development | Very low | Multi-year development timeline |
| Successful approval in osteoporosis | Remote | Potential specialty osteoporosis product |
| Narrow indication with cardiovascular-risk restrictions | Possible only after new evidence | Limited addressable market |
A theoretical approved product could target patients who need potent antiresorptive therapy but cannot tolerate or adhere to existing treatments. The commercial ceiling would depend on cardiovascular labeling, fracture efficacy, reimbursement and competition from generic bisphosphonates, denosumab and newer bone-forming products.
The historical osteoporosis market is large, but that fact does not translate into an odanacatib revenue opportunity. A discontinued asset has no product-level market share, prescription base or reimbursed sales.
Which companies are challenging odanacatib?
No major company is publicly conducting a direct generic or biosimilar challenge to odanacatib.
The competitive pressure comes from marketed osteoporosis therapies rather than direct odanacatib challengers. Relevant companies include:
- Merck, as the original developer.
- Amgen, through denosumab and romosozumab commercialization partnerships.
- Eli Lilly, through teriparatide and related osteoporosis products.
- Teva and generic manufacturers, through bisphosphonate products.
- Novartis, historically through zoledronic acid.
- Radius Health and other developers of anabolic bone therapies.
Biosimilar risk is not applicable to odanacatib because it is a small-molecule candidate and never reached the market. Generic risk would have become relevant only after approval and commercial launch.
What patent litigation affects odanacatib?
No significant active patent litigation affects a marketed odanacatib product.
There is no established U.S. Hatch-Waxman litigation record tied to an approved odanacatib NDA. No settlement agreement between Merck and an ANDA filer has become part of the product’s commercial history.
Any future dispute would likely involve one of three issues:
- Validity or enforceability of residual compound or formulation patents.
- Ownership or licensing of discontinued clinical and regulatory data.
- Freedom to operate around alternative cathepsin K inhibitors or reformulated products.
What licensing deals involve odanacatib?
Merck was the principal company associated with odanacatib’s development. No major post-discontinuation licensing transaction has established a new commercial sponsor or active global development program.
The asset could theoretically be transferred or licensed, but a transaction would carry substantial clinical and regulatory liabilities. The buyer would need rights to relevant patents, clinical data, manufacturing information and regulatory correspondence. Patent rights alone would not resolve the stroke-related development risk.
How strong is the odanacatib patent estate?
The patent estate was strategically important during development but is commercially weak today.
| Factor | Assessment |
|---|---|
| Compound protection | Historically significant |
| Regulatory exclusivity | None |
| Orange Book leverage | None |
| Formulation protection | Potentially relevant but uncommercialized |
| Method-of-use protection | Limited by lack of approval |
| Manufacturing barriers | Potentially meaningful for complex synthesis, but not decisive |
| Litigation leverage | Low without an approved product |
| Asset value | Dependent on clinical redevelopment |
The strongest barrier would have been the combination of compound patents, regulatory approval and clinical data. With approval absent, the remaining patents do not provide the same value as an approved-product estate.
What are the likely generic launch scenarios?
There is no current generic launch scenario.
A conventional generic launch would require an approved reference product and an Orange Book framework. Neither exists. If odanacatib were reapproved in the future, generic entry would depend on remaining patent terms, regulatory exclusivity, formulation claims and any court settlements.
The most plausible present scenario is continued noncommercial status. Odanacatib is not an active branded product facing an imminent generic challenge.
Key Takeaways
- Odanacatib, or MK-0822, was Merck’s oral cathepsin K inhibitor for osteoporosis.
- Merck discontinued development in 2016 after an increased stroke risk emerged in the Phase 3 LOFT study.
- The drug showed meaningful fracture-risk and bone-density benefits but did not achieve an acceptable overall benefit-risk profile.
- Odanacatib has no FDA approval, Orange Book listing, approved indication or regulatory exclusivity.
- No meaningful Paragraph IV challenge, generic launch, biosimilar program or patent settlement exists.
- Historical compound, formulation and method-of-use patents may exist, but their commercial value is limited without an approved product.
- The base-case revenue projection is zero.
- A redevelopment program would require new evidence addressing cerebrovascular safety and would face strong competition from bisphosphonates, denosumab and bone-forming therapies.
FAQs About Odanacatib
Is odanacatib still being developed?
No. Merck discontinued development in 2016 after a stroke-risk signal in the LOFT Phase 3 study.
Is odanacatib available by prescription?
No. Odanacatib was never approved or commercially launched.
Did odanacatib work for osteoporosis?
Yes. Phase 3 data showed reductions in vertebral, hip and nonvertebral fractures, along with increased bone mineral density. The stroke risk prevented further development.
Is odanacatib a biologic or a small molecule?
Odanacatib is an orally administered small-molecule cathepsin K inhibitor. Biosimilar competition is therefore not applicable.
Could odanacatib return to the market?
A return would require a new sponsor or renewed development program capable of resolving the stroke-risk issue. No active program or regulatory filing has established such a path.
References
-
Merck & Co., Inc. (2016, September 13). Merck provides update on investigational osteoporosis medicine odanacatib. Merck press release.
-
Amgen Inc. (2024). Prolia and Evenity prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
-
ClinicalTrials.gov. (n.d.). Long-term odanacatib fracture trial: LOFT. U.S. National Library of Medicine.
-
International Osteoporosis Foundation. (2024). Osteoporosis and fragility fractures. International Osteoporosis Foundation.
More… ↓
